Compagnie Lombard Odier SCmA Buys 529 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Compagnie Lombard Odier SCmA increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1,706.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 560 shares of the biopharmaceutical company’s stock after acquiring an additional 529 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Gilead Sciences were worth $52,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. FMR LLC increased its stake in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after buying an additional 14,680,161 shares during the period. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares during the period. Pacer Advisors Inc. increased its position in shares of Gilead Sciences by 723.3% in the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after acquiring an additional 5,653,075 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after acquiring an additional 1,793,145 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 1.8 %

NASDAQ:GILD opened at $104.08 on Friday. The company has a market cap of $129.71 billion, a PE ratio of 1,156.44, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a 50 day simple moving average of $93.63 and a two-hundred day simple moving average of $87.37. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $106.69.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Research analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 854.05%.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 710,500 shares of company stock valued at $67,684,956. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on GILD shares. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Oppenheimer increased their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Finally, DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $101.33.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.